Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12165054 | 0.83 | ALOX5AP (0.34) | P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL12164960 | 0.82 | MEN1 (0.39) | GABRA1GABRB2P2RX1P2RX3P2RX4 | |
| SCHEMBL12653484 | 0.82 | P2RX1 (0.32) | P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL12164883 | 0.82 | SCN9A (0.37) | P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL12164952 | 0.82 | RAB9A (0.37) | P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL12164884 | 0.82 | SCN9A (0.37) | P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL12165112 | 0.78 | MAOB (0.39) | P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL12165041 | 0.78 | PDK2 (0.39) | P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL12164970 | 0.78 | EHMT2 (0.53) | — | |
| SCHEMBL12165105 | 0.78 | PDK2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| WO-2011053697-A1 | 2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | GENZYME CORPORATION (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | PNMT, AADAT, INMT | GABRA1 2340/4885GABRB2 1977/4885P2RX1 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.